Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

About this update from Aura Biosciences, Inc.

[{"type":"text","content":"Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September 12, 2024\nBOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that Phase 2 end of study data evaluating suprachoroidal administration of bel-sar for the first-line treatment of patients with small choroidal melanoma and indeterminate lesions will be presented at The Retina Society Annual Meeting being held September 11-15, 2024, in Lisbon, Portugal. The presentation details are as follows: Title: Final Results of a Phase 2 Trial of Suprachoroidal Administration of Belzupacap Sarotalocan (bel-sar, AU-011) for Choroidal MelanomaPresenter: Dr. Ivana Kim, MD, Mass Eye and EarDate/Time: Thursday, September 12, 2024, from 11:04 am to 11:09 am Western European Daylight Time (6:04 am to 6:09 am Eastern Time) The presentation will be available here on Thursday, September 12, 2024, following the presentation. In addition, Aura will host a virtual ocular oncology investor event featuring Dr. Ivana Kim, MD (Mass Eye and Ear) and Dr. Prithvi Mruthyunjaya, MD, MHS (Stanford University Byers Eye Institute) to discuss the Phase 2 end of study data on Thursday, September 12, 2024, at 8:00 am Eastern Time. To register for the event, click here. A live question and answer session will follow the formal discussion. The live webcast of Aura’s virtual ocular oncology investor event will be available on the “Investors & Media” page under the “Events & Presentations” section of Aura’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date. About Ivana K. Kim, MD As a member of Mass Eye and Ear's Retina Service, Ivana K. Kim, MD specializes in the medical and surgical treatment of patients with vitreoretinal diseases, including age-related macular degeneration, retinal detachment, and uveal melanoma. In addition to her clinical responsibilities, Dr. Kim is Co-Director of the Harvard Ophthalmology Age-Related Macular Degeneration (AMD) Center of Excellence-a multidisciplinary collaboration among clinicians and scientists who are pooling their knowled...

More updates from Aura Biosciences, Inc.